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Building biomedical 
materials layer-by-layer 
One of the most rapidly growing means of generating thin films in 
the field of materials science has been the alternating adsorption 
based layer-by-layer (LbL) assembly method. This method is 
based on the simple alternating adsorption of complementary 
multivalent species on a substrate via electrostatic interactions, 
hydrogen bonding, or other secondary interactions1-3. LbL assembly 
has particular potential in the area of biomaterials4-9 because 
it enables nanometer level control of the composition of a thin 
film, and the generation of highly complex, tailor-made coating 
compositions10,11; however, unlike other molecular level deposition 
techniques, thin films are constructed in water at room temperature, 
preserving the activity of sensitive proteins, nucleic acids, and other 
functional biomacromolecules. It has been demonstrated that LbL 
multilayers can beautifully and conformally coat structures as 
small as 10 nm diameter gold nanoparticles12,13, and surfaces with 
nanoscale complexity, and yet can also be used to coat large scale 
macroscopic three-dimensional objects. Finally, multilayer thin 
films can be designed to exhibit high levels of biocompatibility14-18 
both in vitro and in vivo, and can be used to incorporate both large 
and small molecules, as well as a number of organic and inorganic 
nanomaterials. A particularly unique aspect of this approach is the 
ability to build drugs in separate sets of layers, with the potential 
for sequential delivery19,20. These properties enable us to explore 
LbL as a means of achieving controlled drug release from thin films 
and coatings with high drug density (Fig. 1). 
Several common paradigms of traditional polymer encapsulation 
are shifted when we examine the enabling approach of alternating 
assembly. It becomes possible to consider the incorporation of very 
different types of drug molecules at high loadings without the same 
issues of stability that are problematic to polymer blends. The potential 
for co-release of two or more drugs with different release profiles, or 
even time-dependent staged delivery becomes plausible through the use 
of top-down compartmentalized regions of LbL thin films19-21. Finally, 
several different modes of release can be introduced using this versatile 
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technique through various means of passive and active film disassembly, 
destabilization, or degradation. In the next decade, it will be important 
to move LbL approaches beyond laboratory successes and toward clinical 
translation. Such translation relies on the ability to show the power of 
multilayer systems in meaningful biomedical applications, as well as the 
potential for commercial manufacturability of the LbL process. The field 
has been growing rapidly, and many researchers have contributed to 
the development of new LbL drug delivery systems7,9,22; in this review 
perspective, a few selected examples from our research team will be 
provided in three general areas. Among the systems discussed, emphasis 
is placed on those that have been demonstrated with in vitro and in vivo 
studies, and on demonstrations of the use of rapid assembly and versatile 
LbL application methods that can help to move LbL biomaterials systems 
from lab to clinic with true translation to pharmaceutical and biomedical 
applications. 
Controlling release of therapeutics from 
surfaces
A unique advantage to the use of LbL assembly is its ability to incorporate 
drugs in high concentrations within a multilayer thin film. Traditional 
polymers used in blends with small molecules for release matrices 
can generally only incorporate 2 to 5 wt% drugs while maintaining 
reasonable stability; larger quantities tend to lead to phase separation, 
destabilization of the blend, and bolus release behavior. In an alternating 
LbL assembly that consists of two to four components, for example, the 
direct adsorption of a pharmaceutical actually utilizes the drug as one of 
the layers within the film, stabilized by electrostatic, hydrogen bonding, 
or a combination of these interactions. The loading of drugs at high 
densities – often ranging from 10 to 40 wt% – with nanofilms that can 
conformally coat a broad range of surfaces creates new opportunities 
for the release of therapeutic molecules from surfaces for localized drug 
release. 
Gentamicin is a simple, water soluble aminoglycoside that kills 
bacterial cells by inhibiting their protein synthesis; it is commonly used 
in hospital settings to address Pseudomonas aeruginosa, Escherichia coli, 
Staphylococcus (Staph) and other common bacterial species for skin, 
bone, and soft tissue infections23. When introduced orally, gentamicin 
only resides in the body for a few hours before being eliminated, thus 
significantly lowering the impact of the antibiotic on a local infected 
region. On the other hand, gentamicin has been introduced into polymer 
Fig. 1 Water based layer-by-layer (LbL) assembly methods enable the incorporation of therapeutics directly into a thin film conformal coating. The LbL process involves 
alternate adsorption of charged or other complementary species onto the intended substrate from aqueous solutions. Traditional approaches involve dipping the 
substrate in dilute solutions; more rapid assembly approaches include automated Spray-LbL, which increases the range of substrate types that can be coated. Multiple 
drugs can be incorporated into nanometer scale coatings with precise control of dose and controlled release from biomedical implant and device surfaces.
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composites such as methyl methacrylate based bone cement used for 
securing whole joint orthopedic implants to prevent infections24. The 
limitation of such systems is that gentamicin can only be incorporated 
into the cement at low concentrations without sacrificing the integrity 
of the polymer cement – thus it cannot be used to eliminate an existing 
infection25. By directly layering the positively charged gentamicin 
sulfate (GS) drug molecule with negatively charged polyelectrolytes 
in an alternating LbL tetralayer with a degradable polycation and a 
biologically derived polyanion, it is possible to generate gentamicin 
release thin films that are on the micron to submicron scale in terms 
of thickness, and provide uniform coatings on biomedical implants such 
as orthopedic implants, sutures, cardiovascular, and opthalmalogical 
implants26,27. The degradable component utilized in this example was a 
poly(β-aminoester) (PBAE), shown as Poly1 in Fig. 2a, which is layered 
with GS and polyacrylic acid (PAA)27. When LbL multilayers are built from 
the repeat {Poly1/PAA/ GS/PAA}, the final thin film exhibits a large rapid 
release of gentamicin from the surface, followed by sustained release 
over multiple weeks; this release behavior is due to freely absorbed GS 
molecules incorporated into the film in the final step GS absorption step, 
yielding a combination release mechanism of rapid drug out-diffusion 
plus slow hydrolytic degradation of GS containing layers. In the example 
shown in Fig. 2b, 200 tetralayer films release a total of 550 μg/cm2 
of gentamicin sulfate from a titanium implant surface, with an initial 
rate over the first few days of 11 μg/cm2/day, followed by a constant 
linear release over the following four week period of 4 μg/cm2/day. The 
gentamicin released from the films retains all of its activity, maintaining 
the same potency as the free drug (Fig. 2c). More important with regard 
to the translation of this kind of approach for biomedical implants is 
the demonstration that the released antibiotic can lower infection 
in vivo. Using a rabbit bone infection model, titanium inserts coated 
with the LbL gentamicin film were shown to alleviate even very severe 
established bone infection in animals27 (Fig. 2d, e). 
Fig. 2 Gentamicin sulfate (GS) antibiotic containing LbL films are generated via direct alternation with positively charged gentamicin sulfate in tetralayers with 
poly(acrylic acid) (PAA) and Poly 1 (shown in (a)). (b) Cumulative amount of gentamicin released from[Poly1/PAA/GS/Anion] films. (c) Kirby-Baur assay comparing 
sterilized and unsterilized LbL GS coatings on a titanium rod implant. (d) micrograph of rabbit femor with titanium rod placed in drilled defect (e) Results from first 
infection model indicates significant impact on bacteria count within a highly infected wound site by day four. Reproduced from27 with permission from Elsevier. 
(b)
(a)
(c)
(d)
(e)
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There are numerous important therapeutics that are not charged, 
and do not necessarily have good water solubility. In these cases, it 
is possible to adapt LbL to a range of different carrier species that 
can readily be introduced into multilayer systems. For example, 
polycyclodextrins (PolyCDs) with charged groups can be used to 
sequester hydrophobic drugs such as anti-inflammatory agents, 
and subsequently can be layered into multilayer thin films to create 
stable thin films28. A series of non-steroidal anti-inflammatory drugs 
(NSAIDs)29 were examined for the assembly of a negatively charged 
PolyCD-NSAID complex with PBAE’s that exhibit different rates of 
hydrolytic degradation28. By varying the composition of degradable 
polycation chosen, the rate of degradation could be modulated in these 
systems. On the other hand, for any given degradable polyion, the 
normalized rates of drug release were statistically identical regardless 
of which NSAID was incorporated, yielding a controlled and constant 
release over multiple days and demonstrating a platform technology 
that enables the incorporation of many different molecules while 
achieving predictable release characteristics. The NSAIDS examined, 
including commonly used diclofenac and flurbiprofen, exhibited cyclo-
oxygenase (Cox-2) inhibition when released in vitro to cells stimulated 
to yield an inflammatory response. Release in these films is linear with 
no initial bolus. Therapeutic levels of drug are eluted from film coatings 
just a few hundred nanometers in thickness, with release over several 
days to over four weeks. Hydrophobic antibiotics, including Ciproflaxin, 
which is a broad spectrum antibiotic known for its high efficacy, can 
also be delivered in its active form using PolyCD complexes28. The 
films themselves are clear, thin, highly conformal, and exhibit excellent 
optical properties; ongoing work is now targeted toward development of 
these films for opthalmological applications such as intraocular lenses. 
It is also possible to combine the technique of direct drug incorporation 
with the use of a carrier such as a PolyCD; this kind of approach has 
been successfully demonstrated with the generation of LbL delivery thin 
Fig. 3 (a) Photograph image and (b) TEM micrograph of a cross-section of free-standing (PEO-b- PCL/PAA)60 film. (c) Once films are constructed, thermal cross-linking 
significantly enhances the stability of the film and slows the drug release profile. (d) Change of film thickness as measured by profilometry. The thickness of the as-prepared 
film rapidly decreases upon introduction to PBS buffer, whereas the cross-linked films undergo much slower film deconstruction. (e) cross-linked film releases drugs over an 
extended period of time, (six days for two ourh cross-link, thirteen days for 39 hour cross-linked film). Reproduced from35 by permission of The Royal Society of Chemistry. 
(b)(a)
(c)
(d)
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films that simultaneously release the broad spectrum charged antibiotic 
vancomycin and an anti-inflammatory drug30. 
Micelles, liposomes or other colloidal carriers and nanomaterials such 
as nanoparticles may also be used as drug carriers that can be directly 
introduced into multilayer thin films31-34. Of particular interest is the 
use of simple FDA approved components to generate thin films with a 
broad range of release behaviors. It is possible to generate alternating 
multilayers of the water soluble and biologically safe poly(ethylene 
oxide) (PEO) with poly(acrylic acid) (PAA) at low pH through hydrogen 
bonding between the PEO ether oxygens and the PAA acid groups. We 
have used this knowledge as the basis for the design of LbL thin films 
consisting of alternating drug loaded micelles from block copolymers 
of polycaprolactone (PCL)-PEO with moderate to high molecular 
weight PAA35. The films that are formed at low pH are micron-scale 
in thickness, and generate coatings or cohesive free-standing films, 
as shown in Fig. 335. When these thin films are exposed to a plasma 
pH of 7.4, the acid groups become highly charged, the hydrogen bonds 
are disrupted, and electrostatic repulsion causes the film to rapidly 
disassemble, releasing its contents and dissolving entirely in a matter of 
seconds. Such a rapid release approach may be of interest for the rapid 
delivery of agents to a wound site or the release of oral therapeutics 
on the tongue or cheek, for example. On the other hand, this same LbL 
assembly can be treated using heat, or other methods to dehydrate the 
film and generate anhydride bonds between carboxylic acid groups in 
Fig. 4 Hemostat sponge created for battlefield medicine applications contain LbL films with blood clotting protein, thrombin (shown in a). (b) Spray-LbL enables the 
uniform coating of hydrogen bonded LbL thin films on a highly porous absorbent sponge. (c) In vitro hemostatic activity of film coated gelatin sponge. (d) Time to 
hemostasis following sample applicaon (controls were sponges with a monolayer coating of BPEI). Reproduced from42 with permission from Wiley.
(b)
(a)
(c)
(d)
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the film. Such films erode away at a much slower rate, dependent on 
the degree of anhydride crosslinking, leading to a near-linear release 
of the same cargo over two weeks. The micellar nanocarriers, when 
released, can penetrate the surrounding tissue of an implant, wound 
bed, or surgical incision and deliver cargo to these localized regions 
following the hydrolytic breakdown of the PCL core, which is prone 
to take place over longer time periods than the anhydride. Use of a 
different hydrogen bonding component, such as a polyphenol like 
tannic acid36, yields a different set of release conditions and systems 
that can be incorporated into the film. The hydrogen bonding of PEO 
based micelles with tannic acid, for example, generates films that are 
stable above pH 7.4, thus allowing the integration of a broad range of 
components at biologic pH or lower35. 
For direct translation of these systems toward realistic applications, 
we can introduce a means of rapidly assembling LbL coatings on a 
variety of surfaces. One approach that has proven to be particularly 
versatile is the use of Spray-LbL37-41, in which each alternating 
component is introduced via a short spray exposure of aqueous 
polyelectrolyte or drug solution, followed by a spray rinse. Because 
each cycle for adsorption is reduced to a few seconds, this approach is 
orders of magnitude faster than traditional dip-LbL methods; however, 
another important advantage in the biomedical arena is that it allows 
us to coat a wider variety of surfaces. Flat and uniform, dimensionally 
complex, and highly porous substrates all become available for LbL 
application using this approach. Particularly challenging surfaces include 
those that are both porous and water absorbent, such as gelatin sponges 
that were designed to absorb many times their weight in blood plasma 
to address bleeding and help induce hemostasis. Thrombin (Fig. 4a), a 
native protein that induces rapid hemostasis in a wound by triggering 
a part of the blood clotting cascade, was introduced in a layer-by-layer 
thin film through the simple alternation of thrombin with tannic acid42 
based on hydrogen bonding interactions between the protein and the 
Fig. 5 In vitro studies of bone differentiation with MC3T3 Pre-Osteoblasts. (Left) Bioactive BMP-2 released from LbL films (sample R) induces differentiation of MC3T3 
pre-osteoblasts to an osteoblast phenotype compared with differentiation medium alone (sample D). Alkaline Phosphatase (ALP) staining (red) shows early (day 
six) activation of the bone differentiation cascade; At 28 days of culture Alizarin Red staining for calcium deposition (red), and Von Kossa staining for mineralization 
of the calcium matrix (black) confirm the differentiation process to osteoblasts. (Right) Quantification of the staining signal (three readings on four independent 
experiments; error bar is standard deviation) shows that the increase in activity of BMP-2 released from LbL films (R) over BMP-2 positive control (B)(matched 90 ng/
mL for both samples) is statistically significant. A single factor ANOVA test allowed rejection of the null hypothesis for both assays; a Tukey test showed that B and R 
are statistically different with p < 0.01 for ALP assay. Both B and R outperform differentiation medium alone (D) or growth medium alone(M). GM = growth medium; 
L+β = L-ascorbic acid and β-glycerol phosphate (differentiation factors); F BMP = LbL Film-released BMP-2; BMP = BMP-2 added directly to the medium. Reproduced 
from58 with permission from Elsevier.
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small molecule, which is a key component found in teas and wine 
tannins, and a natural anti-oxidant43. As shown in Fig. 4b and c, the 
original porous morphology of the sponge is preserved using vacuum-
assisted Spray-LbL; the film conformally coats the surfaces of the pores 
without significantly filling the pores, leaving them free and accessible 
for water uptake. The thrombin contained within the films was found to 
be fully active when compared to the free protein, and large therapeutic 
amounts of active thrombin can be incorporated into the sponge due 
to its large surface area. When tested in vivo with a pig spleen bleeding 
model, it was found that upon compression on a heavily bleeding 
wound, even a 10-bilayer treated LbL thrombin gelatin sponge can stop 
bleeding at least three times faster, than the uncoated gelatin sponge. 
Broad spectrum antibiotics, such as vancomycin, can also be coated 
on these sponges to yield systems that remain functional, and can 
even improve the sponge absorbency44. The ability to coat micro and 
even nanoporous materials leads to numerous possibilities in the areas 
of wound care, control of adhesions for surgical implants, and ready 
storage of localized medical treatments in general for emergency care.
New LbL routes to tissue regeneration
An exciting area in which multilayer assembly presents true potential 
is regenerative medicine and tissue engineering4,7,45,46. A number 
of highly sensitive growth factors regulate the differentiation, 
proliferation, and signaling of stem cells that determine the formation 
of new tissues and key processes such as wound healing. These growth 
factors are typically administered directly to tissues of interest with 
bolus injections, or encapsulated in depots that lead to bolus release 
in the body; such mass release of growth factor proteins generally 
leads to a large amount of clearance of the active protein, with only a 
small amount of the expensive biologic therapeutic remaining to exact 
Fig. 6 Combination BMP-2/VEGF growth factors yield higher bone density within implants. Growth factor loading was controlled by varying the number of layers 
dipped on the scaffold. rhBMP-2 released over a period of about one to two weeks, whereas rhVEGF eluted completely within a shorter time period of four to six 
days depending on number of layers used. (a) Release profiles for BMP containing films. (b) Release profiles of VEGF containing films. (c) (Top row) Micro CT results 
of bone tissue formation. Control scaffolds without growth factors produce no detectable bone over the duration of the study (Middle row) In single growth factor 
rhBMP-2 films lacking rhVEGF165, bone formation is restricted to the periphery of the scaffold at four weeks and nine weeks. (Bottom row) As a result of increased 
vascularity, scaffolds releasing rhVEGF165 demonstrate a smooth, continuous profile in the ectopically formed bone which matures from four weeks to nine weeks to 
fill the entire scaffold. Reproduced from60 with permission from Elsevier.
(b)
(a) (c)
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its influence on tissue development47-49. A more extended release 
of smaller, controlled quantities of growth factor would generally 
replicate the natural process of tissue generation, while yielding 
a controlled and localized process with high pharmacological yield; 
however, most polymeric carriers can only contain limited amounts 
of protein in a stable blend formulation due to thermodynamic and 
other practical constraints. Furthermore, key to the maintenance of 
protein activity is the avoidance of solvent, higher temperatures, or 
pH conditions sufficient to denature proteins, conditions that are 
commonly needed to achieve solubilization in traditional materials 
systems. A unique aspect of LbL assembly is the fact that it is an 
all-aqueous, room temperature process that can be readily adapted 
to the incorporation of a broad range of proteins at high loadings50. 
When incorporated from aqueous solutions at appropriate pH and 
ionic strength, it has been shown that proteins in LbL films retain 
their higher order structure and activity51-53. In early experiments, LbL 
films of lysozyme with negatively charged polysaccharides and PBAE 
polymers led to loadings of fully active protein in the milligram range 
(over 1000 μg/cm2) in 10 to 15μm thick thin films54; the film release 
characteristics can be tuned depending on the size and overall charge 
density of the protein and the choice of complimentary polyions from 
a few days to as many as 30 days. The controlled nature of localized 
release from surfaces enables much lower doses of high cost growth 
factors to be effective for specific applications. 
Bone morphogenetic growth factor 2 (BMP2) is one of the key 
growth factors involved in the differentiation of adult mesenchymal 
stem cells to osteoblasts, or bone cells, and is considered a 
potential treatment for the in vivo regrowth of bone for orthopedic 
applications47,48,55-57. By generating thin films that alternate BMP2 
with chondroitin sulfate and a PBAE degradable polycation, delivery of 
Fig. 7 Schematic and data illustrate the coating of microneedles with hydrolytically degradable Poly 1 and lipid-coated PLGA nanoparticles that encapsulate DNA. The 
microneedles are able to penetrate into the mouse ear, from which the thin film elutes over time based on the choice of degradable polycation. DNA that contains 
the luciferase gene is expressed in the mouse ear over a range of timeframes, depending on the number of bilayers and time allowed for release. Reproduced from62 
with permission from Wiley.
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the protein has been achieved in a controlled fashion over a period of 
4 to 7 days or more, depending on the number of layers incorporated 
in the thin films58. The released BMP2 exhibits all of the activity of the 
original BMP2 protein, as shown in Fig. 5; interestingly, in vitro assays 
actually indicate a slight increase in BMP2 activity, likely due to the 
use of polysaccharides that have binding sites on BMP2 and ligands 
for binding target cell receptors, thus increasing the bioavailability and 
uptake of the protein by cells. Conformal coating of osteoconductive 
tricalcium phosphate polycaprolactone composite scaffolds with BMP2 
containing LbL films can generate a tissue engineering matrix. When 
these scaffolds are implanted in the intramuscular regions of rats, well-
formed and oriented bone is formed around the scaffold region. In this 
process, BMP2 protein eluted from the scaffold recruits MSCs from the 
bone marrow to the site of implantation, induces their differentiation 
into osteoprogenitor cells, and their proliferation in the tissue to form 
substantial bone. 
For tissues to integrate effectively into a scaffold or around an 
implant, typically a vascular system that is well-developed is needed to 
provide blood, oxygen and nutrients via blood flow, and a pathway for 
cell precursors to populate the developing tissue56,59. We investigated 
the construction of separate sets of LbL films containing the vascular 
endothelial growth factor (VEGF), which recruits endothelial precursors 
and enables angiogenesis, and BMP260. By generating a series of LbL 
nanolayers that release VEGF, atop a series containing BMP2, it is 
possible to observe the simultaneous but independent release of 
the two factors, with VEGF releasing over a period of two to three 
days and BMP2 releasing over a more extended time period of five 
to seven days (Fig. 6a). The amount of protein released in each case 
Fig. 8 (a) Prussian Blue nanocrystals are redox-active materials that lose their negative charge upon electrochemical oxidation at low chemical potential. (b) Total 
amount of gentamicin released from a Chi(PB/Chi)5-(PB/GS)50 film over 30 minutes at different applied potentials. (c) Drug release profile from a Chi(PB/Chi)5(PB/
GS)75 film with two second pulses of 1.25 V to turn drug release “on”, followed by 30 second pulses at 0.25 V to turn drug release “off”. The films are sufficiently 
stable to allow for on/off, or pulsatile, drug release controlled by the applied potential. (d) Total amount of gentamicin released from a Chi(PB/Chi)5(PB/GS)50 film 
in one hour at different applied potentials. Rep rinted with permission from69.  © 2010 American Chemical Society.
(b)(a)
(c) (d)
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is directly dependent on the number of layers; the modular nature of 
the protein release enables the design of complex release profiles that 
can be independently tuned for each protein type – a capability very 
difficult to achieve with traditional polymer encapsulation methods. 
Also shown in Fig. 6b, the in vivo results of implants comparing 
BMP2-only versus BMP2/VEGF releasing LbL scaffolds illustrate the 
substantial impact of introducing synergistic growth factors. Bone 
in-growth occurs throughout the entire scaffold region, in contrast to 
just the shell around the implant achieved with just BMP2, yielding a 
solid bone structure throughout the scaffold matrix at nine weeks for 
the dual growth factor system. The bone formed with dual growth 
factors is also higher in bone mineral density, and appears to be highly 
vascularized. These results indicate the promise of the LbL approach 
for tissue engineering applications, including the generation of bone 
tissue around orthopedic implants, and bone in large fractures and 
bone defects. By extending the work to additional growth factors that 
stimulate different stem cell and tissue progenitors, great potential 
exists for the in vivo regeneration of cartilage, the repair of large open 
wounds, blood vessel and skin regeneration from a broad range of 
scaffolds and substrates. 
Controlled micro-release thin film platforms
Although, as demonstrated in the preceding examples, LbL is making 
avenues in the delivery of molecules from large macroscopic areas for 
implants and tissue engineering, the method is also particularly well-
suited to the delivery of small but controlled amounts of drug from micron 
scale structures or small thin film surfaces and devices. One area that 
offers rich opportunities for layer-by-layer technology are transdermal 
delivery - applications in which nano- to microgram quantities of a drug 
are delivered across the skin for therapeutic delivery or vaccines. Vaccines 
are a particularly attractive area of potential growth for transdermal 
release because the skin is heavily populated with immunological cells, 
and the typical use of needles presents opportunity for infection and 
greatly lowers patient compliance. A simple transdermal delivery system 
was constructed with LbL films of a model antigen protein, ovalbumin, in 
bilayers with PBAE polycation61. Rapid release occurs with the films due 
to the low charge density and relatively small size of ovalbumin; when 
the films were placed on tape-stripped mouse ears, ovalbumin was taken 
up by the Langerhans cells – dendritic cells that reside in the skin – and 
an immune response was observed through the uptake of ovalbumin to 
the lymph nodes and the release of specific cytokines. Synergistic effects 
can be obtained with the addition of oligonucleotide agents within the 
multilayer film that stimulate T cell response; significantly increased 
amounts of cytokine production and an even more robust immune 
response were observed, demonstrating the power of dual delivery of 
synergistic compounds61.
This early success led to the investigation of more translational 
modes of delivery. The use of tape-stripping in the animal experiment 
was needed to remove the dense stratum corneum, which is the thick 
top layer of skin that is difficult for hydrophilic biomacromolecules 
to penetrate. By coating arrays of microneedles using the Spray-
LbL technique, it is possible to use a physical means of penetrating 
the stratum corneum, while still providing a solid thin film means of 
delivering proteins and/or other biomolecules directly to the lower 
layers of the skin – approximately 20 to 30 microns and lower – where 
the Langerhans and other immunological cells reside62. We have 
demonstrated the delivery of DNA encapsulated within degradable 
lipid-modified poly(L-lactic-co-glycolic acid) (PLGA) nanoparticles; the 
negatively charged DNA nanoparticles are alternated with degradable 
PBAE polycation to achieve nanolayered coatings on PLGA microneedle 
arrays as shown in Fig. 7. In this case, it was possible to show gene 
transfection of cells in the areas of penetration with dose dependent 
response. Transfection was observed even with a low number of 
bilayers, and longer release times or larger numbers of layers led to 
enhanced gene response. The ease of assembly of coated microneedle 
arrays, combined with the rapid process times from Spray-LbL and the 
high efficacy observed in these systems offers great promise for true 
translational applications. Furthermore, applications in the delivery of 
proteins, hormones, DNA, or siRNA for other medical applications may 
also be of interest in the future.
Other areas of interest in multilayer assembly include the release 
of drugs based on electrochemical potential. Here, the concept of 
manipulating charge within the components of LbL thin films to 
cause film destabilization and disassembly can lead to unique means 
of controlling release from patterned drug containing thin films on 
the remote application of small localized fields. Furthermore, LbL thin 
films can be printed directly onto surfaces63-66 for the generation of 
LbL thin film micro-patches that can release different drugs passively 
at different rates from a number of surfaces, and lift-off methods can 
be used to generate free-standing micron-scale elements, which may 
be of interest for microparticle delivery systems. An earlier approach 
to electrochemically stimulated release was first observed when 
redox-active Prussian Blue (iron hexacyanoferrate) nanoparticles, 
capable of undergoing changes in charge from −2 to neutral, were 
introduced into films in the charged state; when small potentials 
were switched on in the film, the negative charge was reversibly 
removed, causing the film to destabilize due to charge imbalance67. 
In more systematic studies, it was possible to show the release of 
large macromolecules68, and finally of a small molecule drug such 
as gentamicin with films of Prussian Blue69, which is a safe, FDA 
approved compound often used for the treatment of heavy metals, as 
shown in Fig. 8; the films can be systematically pulsed multiple times 
to release controlled nano- to microgram quantities of drugs. More 
recently, it has also been possible to generate electrically controlled 
release systems based on the localized disruption of hydrogen 
bonding in LbL thin films composed of biocompatible components70. 
In general, numerous approaches to microfabrication and LbL thin 
film manipulation can lead to unique micro-delivery methods that 
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can be accessed using a broad range of triggers – from temperature 
to remote control field-assisted release.
Conclusions
In conclusion, a number of new possibilities have been opened up 
through the promise of LbL techniques. The conformal nature of this 
thin film process enables the coating of a broad range of biomedical 
devices, including implant surfaces, porous and nonporous scaffolds 
for tissue engineering, and microscale release devices for localized 
delivery within the body or through the skin. The ability of LbL films 
to incorporate a broad range of drugs, including small molecules and 
sensitive biologic drugs, while retaining drug activity is particularly 
enabling, and may open the door to new therapeutic approaches in 
modified implants, wound healing and remediation, cardiovascular 
stents, and passive or actively triggered microscale release to localized 
regions. Remaining challenges in the field include the enhancement 
of mechanical properties, optimization of film assembly conditions to 
enable long term storage of multilayer systems, and the exploration 
of new triggered and responsive release mechanisms. Ultimately, the 
ability to generate materials capable of synergistic and sustained multi-
drug release in the form of an ultrathin conformal coating using new 
rapid assembly methods and approaches that access three-dimensional 
and complex geometries on a commercial scale will provide new 
avenues for translation in the biomaterials field.  
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